[1] Forner A, Llovet JM, Bruix J.Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245-1255.
[2] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell,2011,144(5):646-674.
[3] Rinninella E, Cerrito L, Spinelli I, et al.Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives[J]. J Clin Transl Hepatol,2017,5(3):235-248.
[4] Marx J.Cancer research. Inflammation and cancer: the link grows stronger[J]. Science,2004,306(5698):966-968.
[5] Prinz I, Silva-Santos B, Pennington DJ.Functional deve-lopment of γδ T cells[J]. Eur J Immunol,2013,43(8):1988-1994.
[6] Philip M, Rowley DA, Schreiber H.Inflammation as a tumor promoter in cancer induction[J]. Semin Cancer Biol,2004,14(6):433-439.
[7] Chien YH, Meyer C, Bonneville M.γδ T cells: first line of defense and beyond[J]. Annu Rev Immunol,2014,32:121-155.
[8] Kabelitz D, Wesch D, He W.Perspectives of gammadelta T cells in tumor immunology[J]. Cancer Res,2007, 67(1):5-8
[9] Deng Y, Du Y, Zhang Q, et al.Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma[J]. Cancer Lett,2014,343(2):161-171.
[10] Mantovani A, Allavena P, Sica A, et al.Cancer-related inflammation[J]. Nature,2008,454(7203):436-444.
[11] Campillo JA, Martinez-Escribano JA, Minguela A, et al.Increased number of cytotoxic CD3+ CD28- gammadelta T cells in peripheral blood of patients with cutaneous malignant melanoma[J]. Dermatology,2007,214(4):283-288.
[12] Patin EC, Soulard D, Fleury S, et al.Type Ⅰ IFN receptor signaling controls IL7-dependent accumulation and activi-ty of protumoral IL17A-producing γδ T cells in breast cancer[J]. Cancer Res,2018,78(1):195-204.
[13] Wang X, Tian Z.γδ T cells in liver diseases[J]. Front Med,2018,12(3):262-268.
[14] Hayday AC.γδ cells: a right time and a right place for a conserved third way of protection[J]. Annu Rev Immunol,2000,18:975-1026.
[15] Albini A, Bruno A, Noonan DM, et al.Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy[J]. Front Immunol,2018,9:527.
[16] Ribot JC, Serre K, Silva-Santos B.Developmental and functional assays to study murine and human γδ T cells[J]. Methods Mol Biol,2017,1514:257-267.
[17] Cai XY, Wang JX, Yi Y, et al.Low counts of γδ T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection[J]. Asian Pac J Cancer Prev,2014,15(2):775-780.
[18] Sugie T, Suzuki E, Yamauchi A, et al.Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer[J]. Breast,2018,38:114-119.
[19] 陈复兴, 刘军权, 冯霞, 等. 人末梢血γδT细胞对消化系统肿瘤细胞的杀伤作用[J]. 世界华人消化杂志,2007,15(14):1591-1595.
[20] Wakita D, Sumida K, Iwakura Y, et al.Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis[J]. Eur J Immunol,2010;40(7):1927-1937.
[21] Ma S, Cheng Q, Cai Y, et al.IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma[J]. Cancer Res,2014,74(7):1969-1982.
[22] Chen J, Fan Y, Cui B, et al.HMGN2: An antitumor effector molecule of γδT cells[J]. J Immunother,2018,41(3):118-124.
[23] Wang J, Lin C, Li H, et al.Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer[J]. Oncoimmunology,2017, 6(11):e1353858.
[24] 刘玲. 观察分析肝硬化及肝癌患者γδT细胞的表达[J]. 临床医药文献电子杂志,2016,3(35):6979.
[25] Yi Y, He HW, Wang JX, et al.The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner[J]. J Hepatol,2013,58(5):977-983.
[26] Mangan BA, Dunne MR, O′Reilly VP, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vdelta3 T cells[J]. J Immunol,2013,191(1):30-34.
[27] Lalazar G, Preston S, Zigmond E, et al.Glycolipids as immune modulatory tools[J]. Mini Rev Med Chem,2006, 6(11):1249-1253.
[28] Harly C, Peyrat MA, Netzer S, et al.Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells[J]. Blood,2011,117(10):2864-2873.
[29] Pang YL, Zhang HG, Peng JR, et al.The immunosuppressive tumor microenvironment in hepatocellular carcinoma[J]. Cancer Immunol Immunother,2009,58(6):877-886.
[30] Cui J, Wang N, Zhao H, et al.Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma[J]. Int J Cancer,2014,134(2):342-351.
